Researchers seek to understand brain's immune response to metastasized cancer

September 25, 2012
Researchers seek to understand brain's immune response to metastasized cancer

Brain metastases are common secondary complications of other types of cancer, particularly lung, breast and skin cancer. The body's own immune response in the brain is rendered powerless in the fight against these metastases by inflammatory reactions. Researchers at the MedUni Vienna have now, for the first time, precisely characterised the brain's immune response to infiltrating metastases. This could pave the way to the development of new, less aggressive treatment options.

"The active phagocytes are quite literally overwhelmed by the tumour and even the white blood cells are too weak to fight off these metastases on their own; they have to be stimulated before they can have any effect," explains oncologist Matthias Preusser from the University Department of Internal Medicine I and the Comprehensive Cancer Center (CCC), a joint institution operated by the MedUni Vienna and the Vienna General Hospital.

was obtained for investigation from autopsies carried out on people who had metastatic disease secondary to breast, lung or skin cancer. These are also the most common types of primary tumour. develop because they spread from the tumours into other parts of the body right up to the brain.

The scientists at the Clinical Institute of Neurology, the Centre for Brain Research, the CCC and the University Department of Internal Medicine I have discovered that metastases in the brain do encounter a wall of , but it is too weak to successfully arrest the tumour's development. To do this, white blood cells (lymphocytes) need to be mobilised in greater numbers as the second instance of the system.

These findings could lead to new therapeutic strategies being developed that will aim to increase the activation of or other parts of the immune system – perhaps through medication such as antibody treatments or vaccines.

300 to 400 patients with brain metastases are treated each year at the MedUni Vienna. The standard treatment in most cases is radiotherapy to the head or generalised irradiation of the brain – which is associated with certain risks and possible side effects. Only in very few cases are drug-based treatment methods available for certain . Says Preusser: "Our findings could represent an important step towards the development of less aggressive forms of treatment."

The study has been drawn up across various disciplines at the Clinical Institute of Neurology, the Department of Neuroimmunology at the Centre for and at the Comprehensive Cancer Center (CNS Tumours Unit). Author Anna Sophie Berghoff from the CCC presented the findings of the study at a lecture given at the Congress of the European Association of Neuro-Oncologists (EANO) in Marseilles.

Explore further: Trastuzumab and chemotherapy improved survival in HER2-postive breast and brain cancer patients

More information: Anna Sophie Berghoff, Hans Lassmann, Matthias Preusser, Romana Höftberger. Characterization of the inflammatory response to solid cancer metastases in the human brain Clin. Exp. Metastasis, 2012, DOI:10.1007/s10585-012-9510-4

Related Stories

Trastuzumab and chemotherapy improved survival in HER2-postive breast and brain cancer patients

July 18, 2011
The use of trastuzumab, chemotherapy and surgery among women with HER2-positive metastatic breast cancer significantly improved survival from the time central nervous system metastases were diagnosed.

Scientists develop first snap shot of tiny brain tumours

March 27, 2012
(Medical Xpress) -- A new imaging technique may be able to detect cancers that have spread to the brain while they are still small.

New drug shrinks brain tumours in melanoma patients

May 21, 2012
(Medical Xpress) -- Australian researchers have reported promising results with a new drug that shrinks brain tumours in melanoma patients. Their findings are published in The Lancet medical journal today.

Potential new therapeutic target for a subset of aggressive breast cancers

March 1, 2012
Scientists from the Max Planck Institute for Heart and Lung Research in Bad Nauheim have now discovered that they can prevent the formation of metastases by blocking the receptor protein Plexin B1.

Mechanism for more efficient cancer treatment decoded

January 19, 2012
(Medical Xpress) -- A research team from the Institute for Cancer Research at the MedUni Vienna has decoded a previously unknown mechanism of the active ingredient imiquimod in tumour defence. They have been able to prove ...

Recommended for you

A metabolic treatment for pancreatic cancer?

August 15, 2017
Pancreatic cancer is now the third leading cause of cancer mortality. Its incidence is increasing in parallel with the population increase in obesity, and its five-year survival rate still hovers at just 8 to 9 percent. Research ...

Skewing the aim of targeted cancer therapies

August 15, 2017
Headlines, of late, have touted the successes of targeted gene-based cancer therapies, such as immunotherapies, but, unfortunately, also their failures.

Findings pave way for three-drug combination treatment for childhood leukemia

August 15, 2017
UCLA researchers have developed a new approach that could eventually help young people respond better to treatment for acute lymphoblastic leukemia. The scientists discovered in mice that when the production of nucleotides—also ...

Does stronger initial response to cancer treatment predict longer overall survival?

August 15, 2017
It seems like such a simple question: Do patients whose tumors shrink more in response to targeted treatment go on to have better outcomes than patients whose tumors shrink less? Actually, the answer seems simple too. In ...

New study reveals late spread of breast cancer and backs key role of early diagnosis

August 14, 2017
Breast cancer cells that spread to other parts of the body break off and leave the primary tumour at late stages of disease development, scientists from the Wellcome Trust Sanger Institute and their collaborators have found.

Discovery of new prostate cancer biomarkers could improve precision therapy

August 14, 2017
Mayo Clinic researchers have identified a new cause of treatment resistance in prostate cancer. Their discovery also suggests ways to improve prostate cancer therapy. The findings appear in Nature Medicine. In the publication, ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.